Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment

Methotrexate (MTX) is one of the staples of pediatric acute lymphoblastic leukemia (ALL) treatment. MTX targets the folate metabolic pathway (FMP). Abnormal function of the enzymes in FMP, due to genetic aberrations, leads to adverse drug reactions. The aim of this study was to investigate variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotur, Nikola, Lazic, Jelena, Ristivojevic, Bojan, Stankovic, Biljana, Gasic, Vladimir, Dokmanovic, Lidija, Krstovski, Nada, Milosevic, Goran, Janic, Dragana, Zukic, Branka, Pavlovic, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230684/
https://www.ncbi.nlm.nih.gov/pubmed/32344632
http://dx.doi.org/10.3390/genes11040468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230684/
https://www.ncbi.nlm.nih.gov/pubmed/32344632
http://dx.doi.org/10.3390/genes11040468

Ejemplares similares